A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Constellation Pharmaceuticals
Constellation Pharmaceuticals
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
NRG Oncology
Wake Forest University Health Sciences
Columbia University
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
University Health Network, Toronto
Novartis
Icahn School of Medicine at Mount Sinai
Incyte Corporation
Sunnybrook Health Sciences Centre